Updated:
Dreavent
Dreavent Capital is a Boston-based venture capital firm focused on biotech investments. It uses a structured Bio Asset Engineering model that starts from...
Dreavent
Dreavent Capital is a Boston-based venture capital firm focused on biotech investments. It uses a structured Bio Asset Engineering model that starts from confirmed pharmaceutical demand and works backwards to select and develop science, with a pharmaceutical partner engaged before capital is deployed. Spain is the first market for connecting scientific ecosystems to Boston’s biotech infrastructure, via a model designed to scale.
General information
Firm type
Private Equity
Year founded
2020
Location
Region
North America
Country
United States
City
Cambridge
Corporate office
Cambridge, United States
Principals
Gorka Fius
Managing Partner
Wendy Nelson
PhD, Partner
William S. Korinek
PhD, Partner
Brian Gallagher Jr.
PhD, Venture Partner
Charles Kunsch
PhD, Venture Partner
Elaine V. Jones
PhD, Senior Advisor
David Lagares
PhD, MBA, Venture Partner
Carolina Salcedo
PhD, Principal
Rosa Gonzalez
Scouting
Elena Rivas
Scouting
Peter Choo
Asset Lead
Lloyd Appel
CFO
Sector focus
Frequently asked questions
What asset classes does Dreavent target?
Dreavent targets early-stage startups, secondaries, and pre-IPO opportunities.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: